35 Hepatitis C
Hepatitis C is a blood-borne virus that is one of the major causes of liver cirrhosis, hepatocellular carcinoma and liver failure. Identifying women who have hepatitis C during pregnancy means that increase of transmission can be avoided.
While there is currently no way of preventing mother-to-baby transmission of hepatitis C, identifying women who have hepatitis C during pregnancy means that interventions that increase the risk of transmission to the baby can be avoided and effective treatments commenced after the birth or cessation of breastfeeding.
Hepatitis C is a blood-borne virus that is one of the major causes of liver cirrhosis, hepatocellular carcinoma and liver failure. Perinatal transmission is the main source of hepatitis C in Australian children. Babies with hepatitis C are mostly born to mothers who used intravenous drugs, had invasive procedures overseas or have tattoos.
35.1.1 Hepatitis C in Australia
- Rates of notification of hepatitis C: Overall there was a 15% decline in the hepatitis C notification rate in Australia between 2007 and 2016 (from 58.8 to 49.9 per 100,000) . However, since 2012, the rate has increased by 12% (from 44.5 to 49.9 per 100,000), with most of this increase occurring in 2015 and 2016.[ ] In contrast, the age-standardised notification rate of newly diagnosed hepatitis C infection in the Aboriginal and Torres Strait Islander population increased by 25% between 2012 and 2016 (from 138.1 to 172.7 per 100,000) .
- Age: Among women, rates of notification remained stable between 2012 and 2016 in the 40 years and over age group (from 36.9 to 35.6 per 100,000) and declined in the 25–39 age group (from 88.5 to 56.5 per 100,000) and the 15–24 age group in 2016 (45.5 to 25.2 per 100,000) .
- Geographical distribution: The notification rate of newly diagnosed hepatitis C in 2016 was highest in the Northern Territory (76.0 per 100,000), followed by Queensland (58.7 per 100,000), New South Wales (55.0 per 100,000), and Tasmania (54.4 per 100,000). Hepatitis C notification rates either remained stable or increased slightly between 2012 and 2016. In New South Wales, rates increased by 17% between 2015 and 2016 (from 47.1 to 55.0 per 100,000). Rates of notification in 2016 were higher in inner and outer regional areas (65.3 per 100 000) than in remote and very remote areas (46.8 per 100 000) and major cities (41.2 per 100 000) .
Observational studies conducted in Australia also identified people who inject drugsand people in prison as at higher risk of testing positive for hepatitis C antibodies or infection.
35.1.2 Risks associated with hepatitis C in pregnancy
The clearest and most serious risk associated with maternal hepatitis C in pregnancy is transmission of the infection to the baby. There are several factors that influence the risk of mother-to-infant transmission:
- risk of transmission is estimated to be 5.8% (95%CI 4.2 to 7.8%) among antibody–positive and RNA-positive women
- the highest reported transmission rates occur in infants born to mothers who are both hepatitis C and HIV positive, with rates as high as 36%
- risk of transmission is increased with a higher maternal viral load of hepatitis C
- risk is increased with intrapartum invasive procedures (fetal scalp blood sampling or internal electronic fetal heart rate monitoring via scalp electrode) (OR 10.1; 95% CI 2.6 to 39.02) and episiotomy (OR 4.2; 95%CI 1.2 to 14.16)
- transmission does not appear to be influenced by mode of birth or gestational age at birth
- prolonged rupture of membranes may increase the risk of transmission , however this could be related to maternal viral load and length of membrane rupture
- amniocentesis in women infected with hepatitis C does not appear to significantly increase the risk of vertical transmission but very few studies have properly addressed this possibility
- there is no evidence that breastfeeding is associated with an increased risk of hepatitis C transmission to the newborn , unless the nipples are cracked and/or bleeding .
35.2 Testing for hepatitis C infection in pregnancy
Internationally, routine testing of pregnant women for hepatitis C has not been recommended RANZCOG suggests that all pregnant women be tested for hepatitis C .. In Australia,
35.2.1 Targeted versus universal testing
Studies were largely consistent in finding that hepatitis C seropositivity was associated with the following risk factors:
- injecting drug use
- receipt of blood transfusion or organ transplant
- history of tattooing or body piercing
- use of intranasal cocaine
- origin from a country of high prevalence ; these include Africa and central and east Asia .
Additional findings were:
- only high severity risk factors (exposure to intravenous drug use or to the blood of a hepatitis C-positive individual) were significantly associated with testing positive for hepatitis C antibodies (P=0.002)
- age, history of prior pregnancy and healthcare employment were additional considerations .
However, studies have estimated that, compared to universal testing, targeted testing would fail to identify 2.5 to 27% of seropositive women.
35.2.2 Clinical utility of testing
The clinical utility of testing for hepatitis C in pregnancy is limited by the lack of effective treatment options to avoid mother-to-child transmission during pregnancy or childbirth.
However, new treatment options (direct-acting antiviral agents) for people living with hepatitis C have become available and were recently listed on the Australian Pharmaceutical Benefits Scheme (PBS). While these treatments have not been proven to be safe in pregnancy or during breastfeeding , women who are diagnosed with hepatitis C during pregnancy could commence such curative treatment after completion of breastfeeding (or immediately after the birth if the infant is not breastfed), thus reducing their risk of significant liver disease and the risk of perinatal infection for subsequent pregnancies.
In addition, knowledge of a woman’s hepatitis C status means interventions that may increase the risk of mother-to-baby transmission (fetal scalp blood sampling, internal electronic fetal heart rate monitoring via scalp electrode, episiotomy) can be avoided.
35.2.3 Costs of testing
No cost-effectiveness studies relevant to the Australian context were identified. A study in the Netherlands found a modest cost-effective outcome for testing first-generation non-Western womenand a study conducted in the United States found that universal testing was not cost-effective with or without elective caesarean section. However, a study in the United Kingdom found that antenatal testing and postnatal treatment was feasible and effective at an acceptable cost .
At the first antenatal visit, recommend testing for hepatitis C.
Approved by NHMRC in October 2017; expires October 2022
35.2.4 Planned invasive procedures
Testing of women who are to have a planned invasive procedure has been recommended, due to the risk of hepatitis C transmission to the baby.
For women who have not previously been tested and who are having a planned invasive procedure (eg chorionic villus sampling), recommend testing for hepatitis C before the procedure.
Approved by NHMRC in October 2017; expires October 2022
35.2.5 Testing process
If an initial test for hepatitis C antibodies is positive, a confirmatory hepatitis C ribonucleic acid (RNA) test will allow assessment of the potential implications and associated risks for the woman and her baby .
35.2.6 Other considerations
For a woman with a diagnosis of hepatitis C during pregnancy, referral to an infectious diseases specialist or hepatologist, as well as to hepatitis support groups for information and advice, should be made during the pregnancy. This will facilitate provision of accurate information, counselling and linkages for follow-up and treatment if desired after the birth.
35.3 Practice summary: hepatitis C testing
In the antenatal period.
- Aboriginal and Torres Strait Islander health worker
- multicultural health worker.
- Discuss hepatitis C testing
Explain that if hepatitis C is identified during pregnancy, interventions that increase the risk of transmission can be avoided and that effective treatment can be started after pregnancy/breastfeeding.
- Document and follow-up
If hepatitis C testing is undertaken, note the results in the woman’s record and advise the woman of her result. Have a system in place so that women who test positive receive education about further transmission (eg to family members) and ongoing support and their babies are followed up after birth.
- Take a holistic approach
If a woman is found to have hepatitis C, specialist advice on management may be required depending on the severity of disease and the health professional’s expertise. Other considerations include counselling and follow-up.
- NSW Ministerial of Health (2014) Clinical Guidelines for the Management of Substance Use During Pregnancy, Birth and the Postnatal Period. North Sydney: NSW Ministry of Health.
- Hepatitis NSW
- Hepatitis SA
- Hepatitis Victoria
- Hepatitis Queensland
- Hepatitis WA
- Northern Territory AIDS and Hepatitis C Council
- Hepatitis ACT
- Tasmanian Council on AIDS, Hepatitis C and Related Diseases
- ACOG (reaffirmed 2016) Viral Hepatitis in Pregnancy. ACOG practice bulletin; no. 86. Washington (DC: American College of Obstetricians and Gynecologists.
- Aebi-Popp K, Duppenthaler A, Rauch A et al (2016) Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland. J Virus Erad 2(1): 52-4.
- ASHM (2015) Antenatal Testing and Blood-Borne Viruses (Bbvs). Sydney: Australasian Society for HIV Medicine.
- Benova L, Mohamoud YA, Calvert C et al (2014) Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 59(6): 765-73.
- Coretti S, Romano F, Orlando V et al (2015) Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature. Risk Manag Healthc Policy 8: 45-54.
- Cottrell EB, Chou R, Wasson N et al (2013) Reducing Risk for Mother-to-Infant Transmission of Hepatitis C Virus: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med 158(2): 109–13.
- CPS (2008) Vertical transmission of the hepatitis C virus: Current knowledge and issues. Paediatr Child Health 13(6): 529-41.
- Diab-Elschahawi M, Dosch V, Honsig C et al (2013) Evaluation of a universal vs a targeted hepatitis C virus screening strategy among pregnant women at the Vienna University Hospital. Am J Infect Control 41(5): 459-60.
- Dunkelberg JC, Berkley EM, Thiel KW et al (2014) Hepatitis B and C in pregnancy: a review and recommendations for care. J Perinatol 34(12): 882-91.
- El-Kamary SS, Hashem M, Saleh DA et al (2015) Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. J Infect 70(5): 512-9.
- Gagnon A, Davies G, Wilson RD et al (2014) Prenatal Invasive Procedures in Women With Hepatitis B, Hepatitis C, and/or Human Immunodeficiency Virus Infections. Journal of Obstetrics and Gynaecology Canada 36(7): 648-53.
- Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ et al (2015) Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur J Obstet Gynecol Reprod Biol 194: 173-7.
- Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S et al (2011) Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis. Arch Gynecol Obstet 283(2): 255-60.
- Graham S, Harrod ME, Iversen J et al (2016) Prevalence of Hepatitis C Among Australian Aboriginal and Torres Strait Islander people: A Systematic Review and Meta-Analysis. Hepat Mon 16(7): e38640.
- Hahne S, Veldhuijzen I, Wiessing L et al (2013) Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infectious Dis 13(181).
- Islam MM, Topp L, Conigrave KM et al (2013) Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Aust N Z J Public Health 37(4): 311-5.
- Iversen J, Wand H, Gonnermann A et al (2010) Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. Int J Drug Policy 21(6): 471-6.
- Lambert J, Jackson V, Coulter-Smith S et al (2013) Universal antenatal screening for hepatitis C. Ir Med J 106(5): 136-9.
- Liu AJ, An EI, Murray HG et al (2009) Screening for hepatitis C virus infection in methadone-maintained mothers and their infants. Med J Aust 191(10): 535-8.
- McDermott CD, Moravac CC, Yudin MH (2010) The Effectiveness of Screening for Hepatitis C in Pregnancy. Journal of Obstetrics and Gynaecology Canada 32(11): 1035-41.
- Miller ER, Bi P, Ryan P (2009) Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors. Int J Infect Dis 13(2): 201-8.
- NICE (updated 2016) Antenatal Care for Uncomplicated Pregnancies. London: National Institute of Health and Clinical Excellence.
- Panda B, Panda A, Riley LE (2010) Selected viral infections in pregnancy. Obstet Gynecol Clin North Am 37(2): 321-31.
- Poliquin V, Yudin MH, Murphy KE et al (2015) Antepartum Screening for Maternal Infection and Immune Status: Is it Time to Broaden Our Routine? Journal of Obstetrics and Gynaecology Canada 37(12): 1118-21.
- Rac MW & Sheffield JS (2014) Prevention and management of viral hepatitis in pregnancy. Obstet Gynecol Clin North Am 41(4): 573-92.
- RANZCOG (2016) Management of Hepatitis C in Pregnancy. Melbourne: Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
- Reekie JM, Levy MH, Richards AH et al (2014) Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010. Med J Aust 200(5): 277-80.
- Ridley G, Zurynski T, Elliot E (2010) Australian Paediatric Surveillance Unit Biannual research Report 2007–2008. Sydney: Australian Paediatric Surveillance Unit.
- Selvapatt N, Ward T, Bailey H et al (2015) Is antenatal screening for hepatitis C virus cost-effective? A decade’s experience at a London centre. J Hepatol 63(4): 797-804.
- Teutsch S, Luciani F, Scheuer N et al (2010) Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health 10: 633.
- The Kirby Institute (2017a) HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2017. Sydney: The Kirby Institute, UNSW.
- The Kirby Institute (2017b) Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people: Annual surveillance report 2017. Sydney: The Kirby Institute, UNSW Australia.
- Valladares G, Chacaltana A, Sjogren MH (2010) The management of HCV-infected pregnant women. Ann Hepatol 9 Suppl: 92- 7.
- van der Poorten D, Kenny DT, George J (2008) Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders. Med J Aust 188(10): 610-4.
- WHO (2016) Hepatitis C Fact Sheet. World Health Organization. Accessed: 20 December 2016.
- Wilson E & Beckmann M (2015) Antenatal screening for hepatitis C: Universal or risk factor based? Aust N Z J Obstet Gynaecol 55(4): 318-22.